Media Coverage
ATCC Adds Novel In Vitro Model to Expanding Portfolio
ATCC has released an in vitro model system for a key mechanism of invasion and metastasis in lung cancer as the company continues its efforts…
Bioanalysis Zone’s “Ask the Experts” Series on Biosimilars
Summary Biosimilars are subsequent versions of an innovator product and have gained popularity over the last 30 years. This series explores the role of biosimilars,…
Triangle Business Journal: Durham’s BioAgilytix heading into expansion mode
BioAgilytix is beefing up in Durham. The contact research organization is expanding its existing 29,000-square-foot space to roughly 50,000 square feet at 2300 Englert Drive…
Meeting the Rigorous Demands of Biosimilar Pharmacokinetics
Abstract Rapid growth of the market for biosimilar products is expected in the next few years, as the patents for a large number of approved…
Cell-Based Assays Keep Biosimilars on Track
The cell-based assay has become a mainstay of drug development, addressing new concerns raised by the advent of biologics. Whereas small molecule drugs may escape…
How Durham’s BioAgilytix courted a German bioanalytical lab
See the Triangle Business Journal’s feature on BioAgilytix’s acquisition of IPM Biotech.
Building Partnerships with Other CROs
By nature, the idea of CRO partnerships is attractive to Executives and Business Development Teams because such alignments equip their CRO with a more comprehensive,…
How to Win Client Trust as a CRO
The act of building trust with your pharmaceutical and biotech clients is similar to how trust is built between friends – both require time, mutual…
How to Set up a Successful CRO by Surrounding Yourself with the Right Team Members
It is very important for executives of CRO companies to recognize that the most critical factor in making a CRO successful is the people that…
Starting a CRO on Personal Credit
Bioanalysis Zone Regardless of the size of the CRO, the quality of the work that I received was most dependent on the specific team managing…